Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

Core Insights - Phio Pharmaceuticals Corp. has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply of its lead compound PH-762, aimed at future clinical trials [1][2] - The lead clinical candidate PH-762 is being evaluated as an intratumoral therapy for cutaneous carcinomas, with a reported pathological response rate of approximately 65% across all dosing cohorts in its Phase 1b trial [2][5] - The company anticipates FDA engagement regarding the next stage of clinical development in the second quarter of 2026 and has sufficient cash reserves to sustain operations into the first half of 2027 [3] Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to combat cancer [1][4] - The INTASYL technology enhances the body's immune cells to effectively kill cancer cells without the need for formulation enhancements [4] - PH-762 targets the PD-1 gene, which is implicated in various forms of skin cancer, and is being evaluated for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [5]